Cargando…
Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
PURPOSE: The purpose of this study was to report the functional and anatomical outcomes of a prospective study resulting from repeated dexamethasone intravitreal implants in patients with uveitic refractory macular edema. METHODS: Twelve eyes of 9 patients with intermediate and posterior noninfectio...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685094/ https://www.ncbi.nlm.nih.gov/pubmed/29184384 http://dx.doi.org/10.2147/OPTH.S141153 |
_version_ | 1783278589607673856 |
---|---|
author | Zola, Marta Briamonte, Cristina Lorenzi, Umberto Machetta, Federica Grignolo, Federico M Fea, Antonio M |
author_facet | Zola, Marta Briamonte, Cristina Lorenzi, Umberto Machetta, Federica Grignolo, Federico M Fea, Antonio M |
author_sort | Zola, Marta |
collection | PubMed |
description | PURPOSE: The purpose of this study was to report the functional and anatomical outcomes of a prospective study resulting from repeated dexamethasone intravitreal implants in patients with uveitic refractory macular edema. METHODS: Twelve eyes of 9 patients with intermediate and posterior noninfectious inflammatory uveitis complicated with refractory macular edema were regularly reviewed after a dexamethasone intravitreal implant. Patients were examined at baseline, 30, 90, 135, and 180 days with best-corrected visual acuity (BCVA), complete slit-lamp examination, intraocular pressure (IOP), optical coherence tomography, and fluorescein angiography. After 6 months of follow-up, eyes were reassessed to receive a second implant. RESULTS: BCVA significantly improved when comparing the baseline values after the first and second implant (16.2 and 25.8 letters, respectively, 9.6 letters improvements, p<0.05). BCVA was better after the second implant compared to the first one throughout the follow-up, but without statistical significance. Mean central macular thickness (CMT) was 446.3±129.9 μm at baseline and was significantly reduced until day 135 (p<0.05). CMT reductions after the second injection showed a similar pattern, though differences were not statistically significant. Cataract progression was observed in 4 of 8 phakic eyes (50%) after the first implant, and in 2 of 3 phakic eyes following the second implant, with 1 eye requiring cataract surgery. One eye developed an IOP >30 mmHg 30 days after the second implant, treated topically. CONCLUSION: Repeated dexamethasone intravitreal implants in uveitic patients with refractory macular edema can be used effectively in a clinical setting with an acceptable safety profile. |
format | Online Article Text |
id | pubmed-5685094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56850942017-11-28 Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone Zola, Marta Briamonte, Cristina Lorenzi, Umberto Machetta, Federica Grignolo, Federico M Fea, Antonio M Clin Ophthalmol Original Research PURPOSE: The purpose of this study was to report the functional and anatomical outcomes of a prospective study resulting from repeated dexamethasone intravitreal implants in patients with uveitic refractory macular edema. METHODS: Twelve eyes of 9 patients with intermediate and posterior noninfectious inflammatory uveitis complicated with refractory macular edema were regularly reviewed after a dexamethasone intravitreal implant. Patients were examined at baseline, 30, 90, 135, and 180 days with best-corrected visual acuity (BCVA), complete slit-lamp examination, intraocular pressure (IOP), optical coherence tomography, and fluorescein angiography. After 6 months of follow-up, eyes were reassessed to receive a second implant. RESULTS: BCVA significantly improved when comparing the baseline values after the first and second implant (16.2 and 25.8 letters, respectively, 9.6 letters improvements, p<0.05). BCVA was better after the second implant compared to the first one throughout the follow-up, but without statistical significance. Mean central macular thickness (CMT) was 446.3±129.9 μm at baseline and was significantly reduced until day 135 (p<0.05). CMT reductions after the second injection showed a similar pattern, though differences were not statistically significant. Cataract progression was observed in 4 of 8 phakic eyes (50%) after the first implant, and in 2 of 3 phakic eyes following the second implant, with 1 eye requiring cataract surgery. One eye developed an IOP >30 mmHg 30 days after the second implant, treated topically. CONCLUSION: Repeated dexamethasone intravitreal implants in uveitic patients with refractory macular edema can be used effectively in a clinical setting with an acceptable safety profile. Dove Medical Press 2017-11-06 /pmc/articles/PMC5685094/ /pubmed/29184384 http://dx.doi.org/10.2147/OPTH.S141153 Text en © 2017 Zola et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zola, Marta Briamonte, Cristina Lorenzi, Umberto Machetta, Federica Grignolo, Federico M Fea, Antonio M Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
title | Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
title_full | Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
title_fullStr | Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
title_full_unstemmed | Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
title_short | Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
title_sort | treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685094/ https://www.ncbi.nlm.nih.gov/pubmed/29184384 http://dx.doi.org/10.2147/OPTH.S141153 |
work_keys_str_mv | AT zolamarta treatmentofrefractoryuveiticmacularedemaresultsofafirstandsecondimplantoflongactingintravitrealdexamethasone AT briamontecristina treatmentofrefractoryuveiticmacularedemaresultsofafirstandsecondimplantoflongactingintravitrealdexamethasone AT lorenziumberto treatmentofrefractoryuveiticmacularedemaresultsofafirstandsecondimplantoflongactingintravitrealdexamethasone AT machettafederica treatmentofrefractoryuveiticmacularedemaresultsofafirstandsecondimplantoflongactingintravitrealdexamethasone AT grignolofedericom treatmentofrefractoryuveiticmacularedemaresultsofafirstandsecondimplantoflongactingintravitrealdexamethasone AT feaantoniom treatmentofrefractoryuveiticmacularedemaresultsofafirstandsecondimplantoflongactingintravitrealdexamethasone |